Preclinical pharmacodynamic biomarker assays of immune modulation can translate to inform exploratory endpoints of target engagement in first-in-human clinical trial stages of drug discovery
Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34 NCG) mouse model
Gene expression analysis of immune checkpoint therapy in mouse tumor models reveals similarities and differences in immune cell populations and functional processes that reflect response to treatment
Patrick Fadden, in collaboration with Fios Genomics.
To learn more about this project, watch our webinar: The Value of Bioinformatics to Assess Novel Immuno-Oncology Therapies.
A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
Charles River, in collaboration with Nimbus Therapeutics
Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34 NCG mice
Charles River, in collaboration with Nexus Pharma